CombiMatrix develops SARS microarray

April 18, 2003 — CombiMatrix Corp. has designed and made what it says is the first microarray based on Severe Acute Respiratory Syndrome (SARS).

The microarrays were fabricated within 48 hours of publication of the coronavirus genome sequence, believed to be responsible for SARS, the company said in a news release. Researchers can use the microarray technology to develop tests for the virus and discover potential drugs for treating the syndrome, the news release said.

CombiMatrix is an operating group of Newport Beach, Calif.-based Acacia Research Corp.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.